Tasman Health Care | Oncology Research

Research site

Location

Suite 1 Level 3 123 Nerang St, Southport, Queensland, Australia

Site insights

Top conditions

Top treatments

Darolutamide

ERAS-254

Androgen

Radium-223 Dichloride

Aplitibart

Naporafenib

KIN-2787

Trametinib

Pembrolizumab

FMC-376

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

6 of 11 total trials

Status recently updated

A First-in-Human Study of HH160 in Participants With Advanced or Metastatic Solid Tumors

This study is evaluating the safety, side effects, how the body processes HH160, and its early anticancer activity when given alone or with other can...

Not yet enrolling

Enrolling

Solid Tumor

Gastroesophageal Adenocarcinoma

Drug: HH160

A Study Evaluating FMC-376 in Participants With KRAS G12C Mutated Solid Tumors (PROSPER)

The goal of this clinical trial is to evaluate FMC-376 in participants with advanced solid tumors with KRAS G12C mutations. This clinical trial will...

Enrolling

Solid Tumor, Adult

Unresectable Solid Tumor

Drug: FMC-376

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)

Stage 1: To select the optimal dose of naporafenib + trametinib to be studied in Stage 2.Stage 2: To compare progression free survival (PFS) and over...

Active, not recruiting

Advanced or Metastatic NRAS-mutant Melanoma

Drug: Trametinib

Drug: Naporafenib

A Study to Compare Darolutamide Given With Androgen Deprivation Therapy (ADT) and Placebo Given With ADT in Men With Hormone Sensitive Prostate Cancer and Raise of Prostate Specific Antigen (PSA) Levels After Local Therapies (ARASTEP)

Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means that in men who had p...

Active, not recruiting

Biochemically Recurrent Prostate Cancer

Other: Placebo matching darolutamide

Drug: Darolutamide (BAY1841788, Nubeqa)

A Study to Evaluate KIN-2787 in Participants With BRAF and/or NRAS Mutation Positive Solid Tumors

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of KIN-2787 in adults with BRAF/NR...

Active, not recruiting

Melanoma

Solid Tumor, Adult

Drug: KIN-2787 and binimetinib

Drug: KIN-2787

RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)

Researchers in this study want to compare how well drug radium-223 dichloride (Xofigo) and androgen receptor pathway inhibitor (ARPI) therapy work in...

Active, not recruiting

Metastatic Castrate Resistant Prostate Cancer (mCRPC)

Drug: ARPI therapy

Drug: Radium-223 dichloride (Xofigo, BAY88-8223)

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms